🔥 #ESMO26 INTerpath-001, full data (now yes)

On top of RFS HR 0.58 and DMFS HR 0.62:
• Manufacturing success >99%
• >90% of patients got the maximum 34 neoantigens

🔍 Practice-changing? For a population, yes. Two things still to prove:
• Can an mRNA strategy rescue patients primary refractory to neoadjuvant ipi-nivo (no pathologic response)?
• Will it move OS in stage II-IIIB too?

Resuls in @NEJM soon

@myESMO @OncoAlert @Larvol @_SEOM

#Melanoma #Immunotherapy